Skip to Main Content

Go to Main Navigation

ioGenetics, LLC

Company Type:
Small Business (1-10M TTM Revenue)

Increasing resistance to current antibiotics is a growing public health threat. Creative alternatives to antibiotics are needed to meet this challenge. ioGenetics is developing novel first/best-in-class anti-infectives called “DBAF” (Directed Biocide® antibody fusions) to treat difficult infections such as MRSA and Strep. pneumoniae. DBAF are an alternate approach, using targeted delivery to cause lethal damage to microorganisms. The technology platform uses unique rational design based on uTOPE™ immunoinformatic analysis and a proven manufacturing technology, Rpex™, to discover, design, and produce products. Lead products include DBAF for Staphylococcus aureus (including MRSA) and Cryptosporidium.

Site Badges
ioGenetics, LLC
3591 Anderson Street Madison, WI, 53704 United States

Get started

To request access, simply fill out the form below and we will contact you.

Password must:

• Be at least 12 characters in length

• Contain a lowercase letter (a-z)

• Contain an uppercase letter (A-Z)

• Contain a numeral (0-9)

• Contain a special character (%, $, !, @)